This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kalkers, N F Articles by Polman, C H Search for Related Content PubMed PubMed Citation Articles by Kalkers, N F Articles by Polman, C H Social Bookmarking                         What's this?

The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study

Department of Neurology, Magnetic Resonance Centre for Multiple Sclerosis Research, VU Medical Center, PO Box 7057, Amsterdam 1007 MB, The Netherlands, nf.kalkers{at}vumc.nl

F Barkhof

Department of Radiology, Magnetic Resonance Centre for Multiple Sclerosis Research, VU Medical Center, PO Box 7057, Amsterdam 1007 MB, The Netherlands

E Bergers

Department of Radiology, Magnetic Resonance Centre for Multiple Sclerosis Research, VU Medical Center, PO Box 7057, Amsterdam 1007 MB, The Netherlands

R van Schijndel

Department of Clinical Physics and Informatics, Magnetic Resonance Centre for Multiple Sclerosis Research, VU Medical Center, PO Box 7057, Amsterdam 1007 MB, The Netherlands

C H Polman

Department of Neurology, Magnetic Resonance Centre for Multiple Sclerosis Research, VU Medical Center, PO Box 7057, Amsterdam 1007 MB, The Netherlands

Progressive axonal loss is the most likely pathologic correlate of irreversible neurologic impairment in primary progressive multiple sclerosis. In a run-in versus treatment trial, we show that the neuroprotective agent riluzole seems to reduce the rate of cervical cord atrophy and the development of hypointense T1 brain lesions on magnetic resonance imaging.

Key Words: multiple sclerosis • neuroprotection • riluzole

Multiple Sclerosis, Vol. 8, No. 6, 532-533 (2002)
DOI: 10.1191/1352458502ms849xx


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B Healy, P Valsasina, M Filippi, and R Bakshi Sample size requirements for treatment effects using gray matter, white matter and whole brain volume in relapsing-remitting multiple sclerosis J. Neurol. Neurosurg. Psychiatry, November 1, 2009; 80(11): 1218 - 1224. [Abstract] [Full Text] [PDF]

				M. Rovaris, E. Judica, J. Sastre-Garriga, A. Rovira, M. Pia Sormani, B. Benedetti, T. Korteweg, N. De Stefano, Z. Khaleeli, X. Montalban, et al. Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis Multiple Sclerosis, May 1, 2008; 14(4): 455 - 464. [Abstract] [PDF]

				R. Zivadinov, A.C. Banas, V. Yella, N. Abdelrahman, B. Weinstock-Guttman, and M.G. Dwyer Comparison of Three Different Methods for Measurement of Cervical Cord Atrophy in Multiple Sclerosis AJNR Am. J. Neuroradiol., February 1, 2008; 29(2): 319 - 325. [Abstract] [Full Text] [PDF]

				V. W. Yong, F. Giuliani, M. Xue, A. Bar-Or, and L. M. Metz Experimental models of neuroprotection relevant to multiple sclerosis Neurology, May 29, 2007; 68(22_suppl_3): S32 - S37. [Abstract] [Full Text] [PDF]

				M. Rovaris, E. Judica, A. Gallo, B. Benedetti, M. P. Sormani, D. Caputo, A. Ghezzi, E. Montanari, A. Bertolotto, G. Mancardi, et al. Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years Brain, October 1, 2006; 129(10): 2628 - 2634. [Abstract] [Full Text] [PDF]

				E. M. Frohman, M. K. Racke, and C. S. Raine Multiple sclerosis--the plaque and its pathogenesis. N. Engl. J. Med., March 2, 2006; 354(9): 942 - 955. [Full Text] [PDF]

				J. Imitola, T. Chitnis, and S. J. Khoury Insights Into the Molecular Pathogenesis of Progression in Multiple Sclerosis: Potential Implications for Future Therapies Arch Neurol, January 1, 2006; 63(1): 25 - 33. [Abstract] [Full Text] [PDF]

				G. Pryce, Z. Ahmed, D. J. R. Hankey, S. J. Jackson, J. L. Croxford, J. M. Pocock, C. Ledent, A. Petzold, A. J. Thompson, G. Giovannoni, et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis Brain, October 1, 2003; 126(10): 2191 - 2202. [Abstract] [Full Text] [PDF]